| CTNT 0.1608 -5.80% | ZSPC 0.0871 21.48% | ONFO 1.5 124.89% | MYSE 3.3 129.17% | NVDA 198.35 -0.26% | BITO 10.35 0.49% | TZA 5.43 -0.46% | TSLL 13.07 -1.73% | INTC 68.5 5.48% | CAPS 0.5345 -9.25% | HUBC 0.1833 -29.50% | DVLT 0.8375 19.63% | SOXS 20.28 -3.13% | TQQQ 56.43 1.40% | QBTS 21.505 3.34% | AGAE 0.5219 10.57% | HIMS 26.99 11.12% | IONQ 44.68 3.31% | DGNX 0.5556 -0.79% | GRAB 4.02 2.55% | SNAP 6.02 -0.33% | SOFI 19.03 1.28% | SMR 11.41 -2.56% | TSLA 388.9 -0.78% | ITP 0.2 -3.57% | BMNG 1.53 0.66% | SOXL 88.37 2.80% | AMD 278.26 7.80% | RGTI 19.45 1.78% | OPEN 5.27 9.34% | MDCX 0.3003 -0.60% | PLUG 2.86 -2.39% | MARA 11.55 10.32% | NVD 5.81 0.69% | AAL 12.27 0.82% | SQQQ 58.61 -1.40% | IMMP 0.5796 6.54% | HOOD 86.85 -0.54% | ONDS 10.2 1.69% | NVTS 12.37 20.57% | RMSG 2.55 42.46% | BYND 0.782 4.11% | NOK 10.29 3.00% | NFLX 107.79 0.07% | ORCL 178.46 5.09% | SPY 701.66 0.25% | SOUN 7.7 -1.91% | AAPL 263.4 -1.14% | PBM 5.87 103.82% | PLTR 142.76 0.43%

Azenta, Inc. (NASDAQ: AZTA) Overview: A Leader in Life Sciences Solutions

Azenta, Inc. (NASDAQ: AZTA) is a prominent figure in the life sciences sector, specializing in sample exploration and management solutions. The company, formerly known as Brooks Automation, Inc., underwent a rebranding in December 2021 to better reflect its focused vision and services. Azenta operates through two main segments: Life Sciences Products and Life Sciences Services, catering to a diverse clientele including pharmaceutical and biotechnology companies, biorepositories, and research institutes.

The financial outlook for Azenta remains positive, with a stable consensus price target of $38 over recent months. However, Evercore ISI projects a more optimistic future for the company, setting a price target of $62. This optimism is supported by Azenta's strong financial performance, highlighted by a 36% increase in third-quarter earnings per share (EPS). With the fiscal fourth quarter and full year 2025 earnings report on the horizon, investors and analysts alike are keen to see if Azenta can maintain its growth trajectory.

Key Insights:

- Azenta, Inc. operates in the life sciences industry, offering automated cold sample management systems and comprehensive sample management programs.

- The consensus price target for Azenta has remained stable at $38, with Evercore ISI setting a more optimistic target of $62.

- Azenta reported a 36% increase in third-quarter EPS, indicating strong operational performance and supporting the higher price target set by Evercore ISI.

Azenta's upcoming fiscal fourth quarter and full year 2025 earnings report, scheduled for November 21, 2025, is eagerly anticipated. This report will offer further clarity on the company's financial health and its potential for future growth. With key figures like President and CEO John Marotta and CFO Lawrence Lin leading the charge, Azenta is well-positioned to continue its trajectory in the life sciences sector. The consistent price target set by analysts, particularly the bullish outlook from Evercore ISI, underscores the confidence in Azenta's strategic direction and operational success.

Published on: November 20, 2025